Oncologix Tech

Oncologix Tech FCF Yield

Delisted·Sep 9, 2026

The Free Cash Flow Yield of Oncologix Tech (OCLG) as of Oct 28, 2026 is -1,510.82 %. In the previous year, Free Cash Flow Yield was 20,692.40 % — a change of -107.30% (lower).

FCF Yield

-1,510.82 %

YoY

-107.30%

Last updated:

Free Cash Flow Yield of Oncologix Tech is 2017 -1,510.82 % . Free Cash Flow Yield of Oncologix Tech was 2016 20,692.40 % . It decreases by -107.30% lower compared to the previous year.

The Oncologix Tech FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2014
-37,944.74 USD
Jan 1, 2015
-21,642.98 USD
Jan 1, 2016
20,692.40 USD
Jan 1, 2017
-1,510.82 USD
The Oncologix Tech FCF Yield history
YEARFCF YieldYoY
-1,510.82 %-107.30%
20,692.40 %-195.61%
-21,642.98 %-42.96%
-37,944.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncologix Tech Stock analysis

What does Oncologix Tech do? Oncologix Tech, Inc. generates revenue through the operation and manufacture of medical device products. The company collaborates with manufacturers and stakeholders in the United States and South Korea to execute agreements with partners, customers, vendors, and manufacturers. It reviews licenses and sublicense agreements with potential licensors and conducts research and due diligence on potential partners, joint-ventures, and acquisitions in the biotech industry. Oncologix Tech, Inc. seeks additional acquisitions of diagnostic and biotechnology opportunities to expand its portfolio. The firm's primary customers include partners, customers, vendors, and manufacturers within the medical device and biotech sectors. It targets opportunities in diagnostic and biotechnology fields through strategic acquisitions and partnerships. Oncologix Tech, Inc. focuses on executing agreements and conducting due diligence to secure new ventures in the biotech industry. Oncologix Tech, Inc. operates as a medical holding company with a focus on medical device products. It engages in reviewing licenses and sublicense agreements and conducts research on potential acquisitions. The company aims to expand its operations by acquiring diagnostic and biotechnology opportunities in the market. Oncologix Tech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncologix Tech stock

Free Cash Flow Yield of Oncologix Tech is -1,510.82 % in 2017.

Free Cash Flow Yield of Oncologix Tech changed from 20,692.40 % to -1,510.82 %, representing a -107.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Oncologix Tech since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Oncologix Tech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Oncologix Tech

All Key Metrics — Oncologix Tech